FDA Bans Diabetes Drug Avandia for Posing Cardiovascular Risks
The U.S. Food and Drug Administration (FDA) has banned the diabetes medication Avandia from November as it poses cardiovascular risks to patients. Only select categories of patients who have no other option will be allowed to use Avandia (rosiglitazone). These patients need to enroll in special programs to use the drug, the FDA announced.
Previously, the FDA had severely restricted the use of rosiglitazone by patients who have type 2 diabetes. Researchers have found that this drug increases the risk of heart attack by 40%. The FDA’s efforts have resulted in declining use of rosiglitazone. Doctors advise patients still using the drug to switch to safer alternatives.
Europe had banned Avandia last year. Health care experts say instead of Avandia, patients can use Actos, which is a safer alternative.